SLC5A5 Antibody

中文名稱：

SLC5A5兔多克隆抗體
貨號：

CSB-PA835713LA01HU
規格：

￥440
圖片：
Western Blot
Positive WB detected in: Rat stomach tissue
All lanes: SLC5A5 antibody at 3.7μg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 69 kDa
Observed band size: 69 kDa

IHC image of CSB-PA835713LA01HU diluted at 1:500 and staining in paraffin-embedded human colon cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

IHC image of CSB-PA835713LA01HU diluted at 1:500 and staining in paraffin-embedded human pancreatic cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

Immunofluorescence staining of MCF-7 cells with CSB-PA835713LA01HU at 1:166, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) SLC5A5 Polyclonal antibody
Uniprot No.：

Q92911
基因名：

SLC5A5
別名：

Na(+)/I(-) cotransporter antibody; Na(+)/I(-) symporter antibody; Na+/I- cotransporter antibody; Na+/I-symporter antibody; NIS antibody; SC5A5_HUMAN antibody; Slc5a5 antibody; sodium iodide symporter antibody; Sodium-iodide symporter antibody; Sodium/iodide cotransporter antibody; Solute carrier family 5 (sodium iodide symporter) member 5 antibody; solute carrier family 5 (sodium/iodide cotransporter), member 5 antibody; Solute carrier family 5 member 5 antibody; TDH1 antibody
宿主：

Rabbit
反應種屬：

Human, Rat
免疫原：

Recombinant Human Sodium/iodide cotransporter protein (547-643AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，SLC5A5 Antibody (CSB-PA835713LA01HU)，的標記方式是Non-conjugated。對于SLC5A5 Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA835713LB01HU	SLC5A5 Antibody, HRP conjugated	ELISA
FITC	CSB-PA835713LC01HU	SLC5A5 Antibody, FITC conjugated
Biotin	CSB-PA835713LD01HU	SLC5A5 Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, WB, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:500-1:1000
IF	1:50-1:200

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Mediates iodide uptake in the thyroid gland.
基因功能參考文獻：
1. The present work reveals much lower iodide affinity in the pocket of human SMCT1 analogous to the putative iodide-binding pocket of human NIS. PMID: 29131623
2. The expression of NIS differs insignificantly in gastric tissue of obese and control individuals. PMID: 29631680
3. NIS localization in the follicular lumen in nodular goiter patients PMID: 28190186
4. Results show transgene induction under hypoxia in tumor cell spheroid models, or radioiodide uptake using sodium iodide symporter (NIS). PMID: 27458162
5. Data suggest iodination of TG is involved in regulation of NIS expression in thyroid follicle via TSH/TSHR signaling; NIS expression and PKA activity are up-regulated by lowly iodinated TG; NIS expression is down-regulated and PKC activity up-regulated by highly iodinated TG. (TG, thyroglobulin; NIS, sodium/iodide symporter; PK, protein kinase; TSH, thyroid-stimulating hormone; TSHR, thyroid-stimulating hormone receptor) PMID: 28396984
6. Data indicate that although fewer than 25% of cells expressed Na+/I- symporter (NIS), combining131I- with gemcitabine (GEMGEM/131I)- caused dramatic tumor regression in NIS-transduced breast cancer brain metastases (BCBMs). PMID: 27363025
7. Experiments in whole cells demonstrated that these four residues participate in transport by NIS: mutations at these positions result in proteins that, although expressed at the plasma membrane, transport little or no I(-) These residues are conserved throughout the entire SLC5 family, to which NIS belongs, suggesting that they serve a similar function in the other transporters PMID: 27562170
8. Study brings out molecular evidence showing that NIS is a direct target of wild-type p53 and its activation upon Doxorubicin drug exposure results in suppression of NIS expression and function in breast cancer cells. PMID: 28528452
9. radiotracer accumulation in transfected cells correlated with the induction of hNIS and with the expression of miRNAs detected by real time PCR. PMID: 28493972
10. Results indicate that Na+/I- symporter (NIS) can be used as an objective used as an objective criterion for determining the sensitivity of luminal B and basal breast cancer (BC)subtypes to neoadjuvant chemotherapy (NACT). PMID: 28361851
11. Our findings indicated that hTERT promoter-driven expression of the NIS gene in HeLa cells led to 188Re uptake and therapeutic effects. Thus, NIS-based gene therapy and imaging using the hTERT promoter and 188Re may be possible. PMID: 27573304
12. SLC5A5 was down-regulated in FTC and PTC. Its expression could be modulated by hsa-let-7f-5p. ATC showed a loss of SLC5A5/hsa-let7f-5p correlation PMID: 26960757
13. Mutating the sites located on the C-terminal domain of the protein has no effect except for the creation of a diacidic motif that decreases the total NIS protein level without affecting its expression at the plasma membrane. PMID: 26831514
14. Therefore, enhancing functional NIS by the increasing level of glycosylation may be suggested as a promising therapeutic strategy for cancer patients who show refractory response to conventional radioiodine treatment. PMID: 26599396
15. Our results confirmed that NIS overexpression enhances the sensitivity of ER-negative breast cancer cells to radioiodide therapy. PMID: 25955347
16. miR-146b-3p binds to the 3'-untranslated region of PAX8 and sodium/iodide symporter, leading to impaired protein translation and a subsequent reduction in iodide uptake. PMID: 26282166
17. Study demonstrates an association of one variant and several haplotypes of the NIS gene with differentiated thyroid cancer. PMID: 26160439
18. Data suggest that SLC5A5, SLC5A8 (sodium-coupled monocarboxylate transporter 1), and SLC26A4 (pendrin), the 3 known iodide transporters, are important in breast tissue metabolism in lactation and in breast neoplasms. [REVIEW] PMID: 26285906
19. Real time PCR revealed that both cell lines express mRNA of lactoferrin receptors while flow cytometry and confocal microscopy showed the cells efficiently internalize bLf which upregulates NIS expression. PMID: 26213306
20. Although the affinity of NIS for I- is low, it increases when Na+ is bound. NIS takes advantage of the extracellular Na+ concentration and the pronounced increase in its own affinity for I- and for the second Na+ elicited by binding of the first. PMID: 24888603
21. concluded that NIS-mediated RAIU could be modulated by miR-146b; accordingly, miR-146b might serve as one of targets to enhance efficacy of radioactive therapy against poorly differential thyroid carcinoma PMID: 25960292
22. In normal salivary gland, striated duct cells strongly expressed NIS. In Warthin's tumors, eosinophilic epithelial cells exhibited NIS expression, but expression was varied among cases. Tc-positive specimens were NIS+. Tc-negative specimens were NIS-. PMID: 25199743
23. Due to their low NIS expression, TCV and DSPTC need higher cumulative doses of radioactive iodine therapy to improve their prognosis. PMID: 24096868
24. results indicate that the NIS mutation rate is very low in the Guangxi Zhuang Region, China, and it is necessary to study mutations of other genes that have major effects on thyroid dyshormonogenesis and have not as yet been studied in this population. PMID: 25465605
25. Relatively weak melanoma-specific promoter directs high NIS activity in melanoma cell, however weaker cancer-specific promoters drive high NIS activity only in certain melanoma cell line. PMID: 25842835
26. BRAF V600E inhibited NIS expression by the upregulation of its promoter methylation. Specific regions of CpG islands of NIS promoter in BRAF V600E harboring papillary thyroid carcinoma were highly methylated compared with surrounding normal tissue. PMID: 25378232
27. Given the recent progress in the study of NIS regulation as molecular basis for new therapeutic approaches in extrathyroidal cancers. PMID: 24884806
28. The expression of TSHR and NIS genes is differently controlled by multiple mechanisms, including epigenetic events elicited by major signaling pathways involved in thyroid tumorigenesis. PMID: 24353283
29. NIS is a new ovarian cancer marker, opening a door for the use of radioiodide in the diagnosis and treatment of ovarian cancer patients. PMID: 24708099
30. this study identified a new distal enhancer, NIS distal enhancer, that regulates gene expression through DNA methylation in thyroid cancer. PMID: 24432988
31. The results suggest a a key structural role for the delta-amino group of R124 in the Na+/I- symporter's maturation and cell surface targeting. PMID: 23690546
32. NIS expression is tightly modulated during the transition of intercalated to striated ducts and striated to excretory ducts in salivary ductal cells. NIS expression in salivary glands is decreased during inflammation and tumor formation PMID: 23441638
33. Data indicate that Na+/I- symporter and type 3 iodothyronine deiodinase genes are expressed in term placenta and amniotic membrane. PMID: 23857380
34. the NIS gene is a direct target of the p53 family. PMID: 24052075
35. SLC5A5 is composed of 13 transmembrane helices and 643 amino acid residues in humans. (Review) PMID: 23988430
36. Data indicate that interhelical interaction is required for Na(+)/I(-) symporter (NIS) folding and activity. PMID: 23650190
37. Data from mutant recombinant proteins suggest that proto-oncogene PBF/PTTG1IP (pituitary tumor-transforming 1 interacting protein) is phosphoprotein and highlight importance of tyrosine residue Y174 in its interaction/co-localization with NIS. PMID: 23678037
38. MEK inhibition leads to lysosome-mediated NIS protein degradation in human breast cancer cells PMID: 23404856
39. The study indicates a positive link between hNIS and ER expression in breast cancer. PMID: 23342072
40. NIS is highly expressed in early human trophoblast at the feto-maternal interface. PMID: 23174149
41. Data indicate that MV-NIS, an oncolytic measles virus that encodes the human thyroidal sodium iodide symporter (NIS), deliver targeted radiotherapy to the tumor site and promote a localized bystander effect. above and beyond that achieved by MV alone. PMID: 23134812
42. Data from various thyroid cancer cell lines suggest that PARP (poly(ADP-ribose) polymerase) inhibition increases NIS gene expression through a particular modulation of transcriptional regulatory mechanisms (i.e., specific histone modifications). PMID: 22982218
43. Data indicate that expression of SLC5A5 in placenta is up-regulated during placentation; during the first trimester, SLC5A5 mRNA is low at 6 weeks and peaks at 12 weeks; expression of SLC5A5 protein increases with increased placental vascularization. PMID: 22954554
44. Nevirapine may induce the up-regulation of NIS mRNA and TSHR mRNA in FRO anaplastic thyroid carcinoma cells. PMID: 22781452
45. Molecular imaging of luciferase signal and sodium-iodide symporter imaging may be useful for in vivo optimization of bioenergetics in transplanted cells. PMID: 23255420
46. Sodium/iodide symporter is expressed in the majority of seminomas and embryonal testicular carcinomas. PMID: 23117572
47. our results established NIS as a carrier protein that interacts with a major cell signaling hub to facilitate tumor cell locomotion and invasion. PMID: 22962269
48. The BRAF(V600E) mutation was associated with a statistically significant lower functional NIS protein expression in the classic variant of papillary thyroid carcinomas. PMID: 23163107
49. CREM expression is increased in thyroid cancer tissue and may play a role in the downregulation of sodium iodide symporter expression in thyroid cancer acting at the transcriptional level PMID: 22510021
50. analysis of subcellular distribution of the sodium iodide symporter in benign and malignant thyroid tissues PMID: 22545753
顯示更多

收起更多
相關疾?。?/div>
Thyroid dyshormonogenesis 1 (TDH1)
亞細胞定位：

Membrane; Multi-pass membrane protein.
蛋白家族：

Sodium:solute symporter (SSF) (TC 2.A.21) family
組織特異性：

Expression is primarily in thyroid tissue, but also to a lower extent in mammary gland and ovary. Expression is reduced in tumors.
數據庫鏈接：

HGNC: 11040

OMIM: 274400

KEGG: hsa:6528

STRING: 9606.ENSP00000222248

UniGene: Hs.584804

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human